RNAi Field Looks to Late-Stage Clinical Data, Approvals to Regain Pharma Interest | GenomeWeb

Though the RNAi field was shaken in late 2010 and early 2011 by the decisions of two major pharmaceutical players to drop their in-house development of oligonucleotide medicines, industry insiders saw a modest renewal of big pharma's interest in the gene-silencing technology in 2012.

However, concerns that RNAi won't live up to its potential remain, making solid clinical demonstrations of its therapeutic utility and even regulatory approvals a must before it will be embraced as warmly as it had in previous years, they said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.